Extrawell Pharmaceutical Holdings (HKSE:00858) ROCE % : -35.69% (As of Sep. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Extrawell Pharmaceutical Holdings's annualized ROCE % for the quarter that ended in Sep. 2023 was -35.69%.

Extrawell Pharmaceutical Holdings ROCE % Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings ROCE % Chart

Extrawell Pharmaceutical Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

6.39

8.16

-9.37

12.34

11.10

Extrawell Pharmaceutical Holdings Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROCE %	Get a 7-Day Free Trial															16.81	7.92	8.43	13.86	-35.69

Extrawell Pharmaceutical Holdings ROCE % Calculation

Extrawell Pharmaceutical Holdings's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	146.537	/	( ( (1317.101 - 64.063)	+	(1444.874 - 57.014) )	/ 2 )
	=	146.537	/	( (1253.038	+	1387.86)	/ 2 )
	=	146.537	/	1320.449
	=	11.10 %

Extrawell Pharmaceutical Holdings's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	-453.558	/	( ( (1444.874 - 57.014)	+	(1204.998 - 51.453) )	/ 2 )
	=	-453.558	/	( ( 1387.86	+	1153.545 )	/ 2 )
	=	-453.558	/	1270.7025
	=	-35.69 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

Extrawell Pharmaceutical Holdings (HKSE:00858) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Extrawell Pharmaceutical Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG

Website

http://www.extrawell.com.hk

Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.

Executives

Mao Yumin	2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited	2201 Interest of corporation controlled by you
Ease Gold Investments Limited	2201 Interest of corporation controlled by you
Jnj Investments Ltd	2201 Interest of corporation controlled by you
United Gene Group Ltd	2201 Interest of corporation controlled by you
United Gene Holdings Limited	2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited	2101 Beneficial owner
Xie Yi	2201 Interest of corporation controlled by you
Huang Zhenping	2101 Beneficial owner
United Gene Industry Group Limited	2101 Beneficial owner
Chen Xuhua	2202 Interest of your spouse
Cheng Yong	2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines